TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.
The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
The conversation is about alternative measures for hair regrowth for those who did not respond to finasteride or dutasteride, including the use of minoxidil and addressing vitamin deficiencies through blood tests.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.
Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.
The user is considering using 2 vials of Fluridil every other day instead of 1 vial daily for better scalp coverage. They are questioning if this method would be as effective.
The user experienced increased shedding and an itchy scalp after switching from Ascend to Aurobindo finasteride. They are considering switching to dutasteride and are concerned about elevated estrogen levels and the effectiveness of adding minoxidil later.
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
A 32-year-old male started taking 0.5mg of finasteride daily for hair thinning and, after 8 weeks, experienced a 70% reduction in DHT and an increase in estradiol; he is currently in the shedding phase of treatment and questioning if the dosage is correct based on his DHT levels. He began with a lower dose due to already low normal testosterone and DHT levels.
An 18.5-year-old experiencing rapid hair loss is being treated with saw palmetto, vitamins, and red light therapy, but these seem ineffective. The consideration of finasteride is discussed, weighing its potential side effects against the emotional impact of early hair loss.
The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.
Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.
The user believes that combining alfatrodial and fluridil with minoxidil effectively maintains hair, based on their 7-year experience. They suggest this combination for those who can't tolerate finasteride.
A user lost 60% hair density in 4 months, started finasteride and microneedling, and has greasy, flaky, yellowish scalp. They are awaiting biopsy results, and another user suggested trying ketoconazole shampoo.
The user is experiencing hair shedding despite starting finasteride 4 months ago, with no signs of miniaturization. They are seeking advice after normal blood tests and similar family experiences.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.